ArticleThe journals of gerontology. Series B, Psychological sciences and social sciences2025
Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach.
Kellen K Petersen, Bhargav T Nallapu, Richard B Lipton, Ellen Grober, Christos Davatzikos, Danielle J Harvey, Ilya M Nasrallah, Ali Ezzati
Abstract read
In one paragraphArticle in The journals of gerontology. Series B, Psychological sciences and social sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Kellen K PetersenDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Bhargav T NallapuSaul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Richard B LiptonSaul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Ellen GroberSaul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Christos DavatzikosCenter for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-1025-8561 Danielle J HarveyDepartment of Public Health Sciences, University of California, Davis, Davis, California, USA.
Ilya M NasrallahCenter for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ali EzzatiSaul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-1307-4589 Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MVascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Richard B. LIPTON · 1985 to 2026
$73.9MValidation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse PopulationsR01AG080635 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Ali Ezzati, Richard B. LIPTON · 2023 to 2026
$8.6MPredictive analytics for cognitive decline and Alzheimer’s diseaseK23AG063993 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EZZATI, ALI · 2020 to 2024
$984kAbbVieAlzheimer's Association SG-24-988292 ISAVRADAlzheimer's Association; Alzheimer's Drug Discovery FoundationAlzheimer's Disease Neuroimaging InitiativeAraclon BiotechBioClinica, Inc.BiogenBristol-Myers SquibbCereSpir, Inc.CIHRCogstateCure Alzheimer's FundDOD ADNI (Department of Defense W81XWH-12-2-0012Eisai IncorporatedElan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche LtdFoundation for the National Institutes of HealthFujikura FoundationGE HealthcareGenentech, Inc.IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLCJohnson & Johnson Pharmaceutical Research & Development LLCLeonard and Sylvia Marx FoundationLumosity; Lundbeck; Merck & Co., Inc.Meso Scale Diagnostics, LLCNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS AG003949NIA NIH HHS AG080635NIA NIH HHS K23 AG063993NIA NIH HHS K23-AG063993NIA NIH HHS P01 AG003949NIA NIH HHS R01 AG080635NIA NIH HHS U01 AG024904NIBIB NIH HHSNIH HHSNorthern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itselfAbstract
objectivesThe aim of this work is to use a machine learning framework to develop simple risk scores for predicting β-amyloid (Aβ) and tau positivity among individuals with mild cognitive impairment (MCI).
methodsData for 657 individuals with MCI from the Alzheimer's Disease Neuroimaging Initiative (ADNI) data set were used. A modified version of AutoScore, a machine learning-based software tool, was used to develop risk scores based on hierarchical combinations of predictor categories, including demographics, neuropsychological assessments, APOE4 status, and imaging biomarkers.
resultsThe highest area under the receiver operating characteristic curve (AUC) for predicting Aβ positivity was 0.79, which was achieved by 2 separate models with predictors of age, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), APOE4 status, and either Trail Making Test Part B (TMT-B) or white matter hyperintensity. The best-performing model for tau positivity had an AUC of 0.91 using age, ADAS-13, and TMT-B scores, APOE4 information, abnormal hippocampal volume, and amyloid status as predictors. DISCUSSION: Simple integer-based risk scores using available data could be used for predicting Aβ and tau positivity in individuals with MCI. Models have the potential to improve clinical trials through improved screening of individuals.
Indexed as
Amyloid beta-PeptidesBrainCognitive DysfunctionMachine Learningtau ProteinsAgedAged, 80 and overAlzheimer DiseaseApolipoprotein E4BiomarkersFemaleHumansMaleNeuroimagingNeuropsychological TestsRisk AssessmentAmyloid beta-PeptidesApolipoprotein E4Biomarkerstau ProteinsAlzheimer’s diseaseDiagnosisRisk score
Identifiers
PMID40326513
PMCPMC12202008
What OpenQuestion holds
Textmetadata
Read underepoch 390